Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
NMTC Catalyst Timeline
Dated clinical, regulatory and corporate events for NeuroOne Medical Technologies Corporation
Past FDA Catalysts and PDUFA Decisions
How NMTC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
NeuroOne Medical Technologies Corporation is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every NMTC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Wambeke David J.Officer (Chief Business Officer) | Buy | 33,333 199,999 held | $2.01 | 08/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NMTC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NMTC for Q3 2026. | ||||
Ownership Trends
NMTC Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How NMTC ranks across every disease it competes in
NMTC News
NeuroOne® Announces Peer-Reviewed Publication of Initial Clinical Experience with OneRF® Trigeminal Nerve Ablation System
NeuroOne Medical Technologies announced positive initial clinical results for its OneRF Trigeminal Nerve Ablation System. A study published in Pain Management showed immediate pain freedom in 14 of 15 patients, with all achieving favorable outcomes at six months. The innovative multi-contact probe technology allowed effective mapping without repositioning, enhancing patient comfort.
Read more →NeuroOne Featured in New York Post on OneRF® Patient’s Remarkable Journey to Overcome Debilitating Facial Pain
NeuroOne Medical Technologies highlighted a feature in the New York Post about Natisha Long, who found relief from trigeminal neuralgia after using the OneRF Trigeminal Nerve Ablation System. This FDA-cleared system allowed her to undergo a minimally invasive procedure, resulting in immediate pain relief. The company aims to expand access to this innovative treatment.
Read more →NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program
NeuroOne Medical Technologies announced a significant milestone by securing its first pharmaceutical industry purchase order for the StereoCED™ Drug Delivery Platform. This order supports a preclinical research program for a Tier 1 global pharmaceutical company, expected to begin in large animals next year. The platform's unique capabilities may enhance drug development processes.
Read more →NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology
NeuroOne Medical Technologies has partnered with Dartmouth College on a $1 million NIH grant to develop advanced neurotransmitter sensing technology. The initial funding of approximately $200,000 will support research through April 2027. This collaboration aims to enhance real-time monitoring of brain activity and neurochemical signaling, potentially improving treatment for neurological disorders.
Read more →NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order
NeuroOne Medical Technologies reported preliminary fiscal Q4 2026 product revenue of $3.8 million, marking a 38.4% increase from the previous year. The company also announced a record purchase order of $4.5 million, contributing to total open orders of $5.4 million. Full-year revenue is expected to reach $10.5 million, reflecting a 15.6% growth.
Read more →NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement
NeuroOne Medical Technologies Corporation announced a new distribution agreement for its FDA-cleared OneRF® Trigeminal Nerve Ablation System in Southern California. This agreement aims to enhance commercial access in a key market, supporting the company's strategy to expand its distribution network. The OneRF® system offers a less invasive treatment option for patients suffering from trigeminal neuralgia.
Read more →NeuroOne Medical Technologies Announces Restatement of Financial Results for Quarter Ending March 31, 2026 Ongoing Business Not Affected, Company Reaffirms
NeuroOne Medical Technologies Corporation has announced a restatement of its financial results for the quarter ending March 31, 2026, due to a revenue overstatement caused by customer order modifications. The company confirmed that this restatement will not impact its product revenue guidance for fiscal year 2026, which remains at least $10.5 million. Despite the need for correction, NeuroOne's ongoing business operations and growth strategies are reported to be stable. The company intends to amend its financial statements and improve internal controls over financial reporting.
Read more →NeuroOne Reports Fiscal Q2 2026 Financial Results and Provides Corporate Business Update
NeuroOne Medical Technologies Corporation has reported financial results for Q2 2026, showing a remarkable 72% increase in product revenue amounting to $2.4 million. The company successfully completed 16 trigeminal neuralgia procedures, with all patients reportedly pain-free. While operational expenses remained consistent, the quarterly net loss decreased slightly when compared year-on-year. The report also highlights future growth prospects with the continued expansion of its product lines and international market reach.
Read more →NeuroOne Reports Fiscal Q1 2026 Financial Results; Expects
NeuroOne Medical Technologies Corporation reported its financial results for the first quarter of fiscal 2026, highlighting product revenue expectations of at least $10.5 million. During this quarter, nearly half of all ablations using the OneRF Ablation System since its launch were completed. The company successfully concluded nine cases for trigeminal neuralgia, with all patients reporting pain relief. However, product revenues faced a slight decline from the previous year, and the company recorded a net loss during this period.
Read more →NeuroOne Appoints Jason Mills to the Board of Directors Med-Tech Research Analyst & Public Company Executive to Bring Strategic Experience, Industry Relationships and Vision to the Board
NeuroOne Medical Technologies Corporation has appointed Jason Mills to its Board of Directors, effective December 18, 2025. Mills brings over two decades of experience in med-tech investment analysis and currently serves as Executive Vice President of Strategy at Penumbra, Inc. His extensive background, including awards for his equity research, is expected to provide valuable insights as NeuroOne progresses with its clinical and corporate goals. The appointment is seen as a strategic move to enhance the company's value in transforming the diagnosis and treatment of neurological disorders.
Read more →NeuroOne Reports Strong Fourth Quarter Fiscal 2025 Financial Results with Product Revenue Growth of 907% to $2.7 Million and 55.8% Gross Margin
NeuroOne Medical Technologies Corporation announced its fiscal 2025 financial results, showcasing robust growth. The company achieved a remarkable 907% increase in product revenue in the fourth quarter, reaching $2.7 million, and a total revenue increase of 163% for the fiscal year, totaling $9.1 million. Contributing to this success was the strong performance of the OneRF Ablation System, alongside achieving FDA 510(k) clearance for the OneRF Trigeminal Nerve Ablation System. The balance sheet also strengthened, positioning the company for further expansion and development in 2026.
Read more →NeuroOne Announces Preliminary Unaudited Product
NeuroOne Medical Technologies Corporation has reported a significant preliminary unaudited product revenue growth of 163%, reaching a record $9.1 million for the fiscal year ending September 30, 2025. This growth is attributed to increased customer interest and favorable outcomes associated with its OneRF Ablation system for epilepsy patients. The company will provide further financial details in December 2025 and is hosting a virtual investor webinar on October 7, 2025, to discuss recent developments.
Read more →NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025
NeuroOne Medical Technologies Corporation will participate in the Sidoti Small-Cap Conference on September 17-18, 2025. CEO Dave Rosa and CFO Ron McClurg will present on September 17 and hold one-on-one meetings with investors. The company reported a 105% revenue increase and received FDA clearance for its Trigeminal Nerve Ablation System.
Read more →NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
NeuroOne Medical Technologies has received FDA clearance for its OneRF® Trigeminal Nerve Ablation System, designed to treat trigeminal neuralgia, a chronic facial pain condition. This minimally invasive system utilizes radiofrequency energy to create lesions in the trigeminal nerve, potentially improving patient outcomes. A limited commercial launch is targeted for late 2025.
Read more →NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%
NeuroOne Medical Technologies reported third quarter fiscal 2025 revenue of $1.7 million, a 105 percent increase from the prior year. Gross margin expanded to 53.9 percent during the same period. The company also completed an $8.2 million capital raise to fund operations through at least fiscal year 2026. Operating expenses decreased by 9 percent to $2.8 million compared to the previous year.
Read more →NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update
NeuroOne Medical Technologies Corporation will release its financial results for the third quarter of fiscal year 2025 on August 14, 2025. The company will also host an investor conference call to discuss these results and provide a corporate update. Interested participants can join the call via provided dial-in information.
Read more →NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office
NeuroOne Medical Technologies Corporation has received a notice of allowance for a key patent from the U.S. Patent and Trademark Office. This patent, titled 'Methods for Making Probe Devices and Related Devices,' covers innovative methods for creating neural probe devices. The company expects the patent to be issued soon, enhancing its intellectual property portfolio, which includes 17 patents related to electrode technologies.
Read more →NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System
NeuroOne Medical Technologies Corporation announced that Clara, an early patient treated with the OneRF® Ablation System, has surpassed one year of being seizure-free. This milestone highlights the effectiveness of the device, which is FDA-cleared for both diagnostic and therapeutic use. The company aims to leverage this technology for further applications, including treating facial pain.
Read more →NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary
NeuroOne Medical Technologies Corporation has appointed Emily Johns as General Counsel and Corporate Secretary. This strategic hire is expected to strengthen the management team and reduce legal costs. Johns brings extensive experience in corporate governance and has previously worked with NeuroOne on transactional matters. She expressed excitement about joining the company during a pivotal time.
Read more →NeuroOne to Attend MedInvest’s MedTech, AI & Digital Health Conference on June 3-4, 2025
NeuroOne Medical Technologies Corporation will participate in the MedInvest MedTech, AI & Digital Health Conference on June 3-4, 2025, in San Francisco. CEO Dave Rosa will meet with investors during the event, which will include discussions on medical devices and digital health technologies. This participation highlights NeuroOne's commitment to advancing surgical care for neurological disorders.
Read more →